Pegylated-Interferon .Alfa. 2B (Peg-Ifn)
Chronic Hepatitis C Virus Infection
Explore 3 assets in Chronic Hepatitis C Virus Infection →Floatz Rating
BBB73/100
Confidence
Indicative
Sponsor
Merck Sharp & Dohme LLC
Modality
protein_peptide
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00687219CT.gov Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116) | — | Completed | — | — | — |
NCT00686881CT.gov Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773) | — | Terminated | — | — | — |
NCT00323804CT.gov Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy. | — | Completed | — | — | — |
NCT00709059CT.gov Efficacy of PegIntron and Rebetol in Previously Untreated Patients With Chronic Hepatitis C Infected With HCV Genotype 1/4/5/6 (Study P04243) | — | Completed | — | — | — |
NCT00811967CT.gov Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED) | — | Terminated | — | — | — |
NCT00049842CT.gov Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED) | — | Completed | — | — | — |
NCT00048724CT.gov Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569) | — | Completed | — | — | — |
NCT00039871CT.gov PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Hepatitis C Virus Infection
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pegylated-Interferon .Alfa. 2B (Peg-Ifn) (this asset) | Merck Sharp & Dohme LLC | P3 | BBB · 73 |
| Dasabuvir | AbbVie | P3 | A |
| Ombitasvir | Ain Shams University | P3 | A |
| Veruprevir | Ain Shams University | P3 | A |
| Ribavirin | Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. | P4 | A |
| Sofosbuvir | Peking University First Hospital | P4 | A |
| Pegyinterferon-Alfa-2A | Hoffmann-La Roche | P4 | A |
| Glecaprevir | Kirby Institute | P3 | A |
| Pibrentasvir | Kirby Institute | P3 | A |
+42 more in the Chronic Hepatitis C Virus Infection cohort
Other indications for Pegylated-Interferon .Alfa. 2B (Peg-Ifn)
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hepatitis C Virus Infection | — | P4 | BB · 70 |
| Fibrotic Liver Disease | — | P3 | BB · 64 |
| Cirrhosis Of Liver | — | P3 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pegylated-Interferon .Alfa. 2B (Peg-Ifn) in Chronic Hepatitis C Virus Infection. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pegylated-interferon-alfa-2b-peg-ifn-chronic-hepatitis-c-virus-infection
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →